OTHER
DOCUMENTS

Alteration of sleep quality occurs in a wide range of neurological and neurodegenerative disorders and could appear during the prodromal phase, before the onset of clinical symptoms. A key feature of preclinical studies is characterizing the effect of compounds on sleep and their ability to restore altered sleep architecture. 

SynapCell’s model-biomarker duo pushes back the limits of EEG and allows you to : 

          🔍   Study the sleep architecture of your CNS disease model

          🌙    Identify aberrant sleep-vigilance states patterns

           🧬   Characterize the impact of a gene mutation on vigilance state patterns

Assess the changes induced by your candidate compound on sleep patterns and on various patterns and on various EEG metrics (spectral power, coherence…)

Thanks to our powerful Machine-learning powered analysis, receive quick, robust results to guide your decision-making.